U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C24H28N2O5
Molecular Weight 424.4904
Optical Activity UNSPECIFIED
Defined Stereocenters 2 / 2
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of BENAZEPRIL

SMILES

CCOC(=O)[C@]([H])(CCc1ccccc1)N[C@@]2([H])CCc3ccccc3N(CC(=O)O)C2=O

InChI

InChIKey=XPCFTKFZXHTYIP-PMACEKPBSA-N
InChI=1S/C24H28N2O5/c1-2-31-24(30)20(14-12-17-8-4-3-5-9-17)25-19-15-13-18-10-6-7-11-21(18)26(23(19)29)16-22(27)28/h3-11,19-20,25H,2,12-16H2,1H3,(H,27,28)/t19-,20-/m0/s1

HIDE SMILES / InChI

Description
Curator's Comment:: description was created based on several sources, including: https://www.drugs.com/pro/benazepril.html | DOI: 10.1111/j.1527-3466.1990.tb00432.x

Benazepril is a prodrug which is metabolized by the liver into its active form benazeprilat via cleavage of the drug's ester group. Benazepril and Benazeprilat inhibit angiotensin-converting enzyme (ACE) in human subjects and animals. Benazeprilat has much greater ACE inhibitory activity than does Benazepril. It is indicated for the treatment of hypertension. It may be used alone or in combination with thiazide diuretics. Adverse reactions reported in controlled clinical trials and rarer events seen in post-marketing experience, include the following: Stevens-Johnson syndrome, pemphigus, apparent hypersensitivity reactions (manifested by dermatitis, pruritus, or rash), photosensitivity, and flushing, nausea, pancreatitis, constipation, gastritis, vomiting, and melena, thrombocytopenia and hemolytic anemia, anxiety, decreased libido, hypertonia, insomnia, nervousness, and paresthesia. Patients on diuretics, especially those in whom diuretic therapy was recently instituted, may occasionally experience an excessive reduction of blood pressure after initiation of therapy with Benazepril. Increased serum lithium levels and symptoms of lithium toxicity have been reported in patients receiving ACE inhibitors (including benazepril) during therapy with lithium.

CNS Activity

Curator's Comment:: Benazepril crossed the blood-brain barrier only to an extremely low extent.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
14.0 nM [IC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
LOTENSIN

Approved Use

Amlodipine besylate and benazepril hydrochloride capsules is a combination capsule of amlodipine, a dihydropyridine calcium channel blocker (DHP CCB) and benazepril, an angiotensin converting enzyme (ACE) inhibitor. Amlodipine besylate and benazepril hydrochloride capsules are indicated for the treatment of hypertension in patients not adequately controlled on monotherapy with either agent (1) 1.1 Hypertension Amlodipine besylate and benazepril hydrochloride capsules are indicated for the treatment of hypertension in patients not adequately controlled on monotherapy with either agent.

Launch Date

6.7780798E11
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
437 pmol/g
10 mg single, oral
dose: 10 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
BENAZEPRIL plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
334 pmol × h/g
10 mg single, oral
dose: 10 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
BENAZEPRIL plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
0.6 h
10 mg single, oral
dose: 10 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
BENAZEPRIL plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
10 mg 1 times / day multiple, oral
Recommended
Dose: 10 mg, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg, 1 times / day
Sources:
unhealthy, adult
n = 116
Health Status: unhealthy
Condition: Essential hypertension
Age Group: adult
Population Size: 116
Sources:
Other AEs: Headache, Back pain...
Other AEs:
Headache (8.6%)
Back pain (2.6%)
Diarrhoea (0.9%)
Upper respiratory tract infection (3.4%)
Peripheral oedema (1.7%)
Sinusitis (1.7%)
Fatigue (0.9%)
Cough (1.7%)
Arthralgia (0.9%)
Sources:
10 mg 1 times / day multiple, oral
Recommended
Dose: 10 mg, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg, 1 times / day
Sources:
unhealthy
n = 193
Health Status: unhealthy
Condition: Essential hypertension
Population Size: 193
Sources:
Other AEs: Headache, Fatigue...
Other AEs:
Headache (9%)
Fatigue (2%)
Nausea (2%)
Dizziness (2%)
Cough increased (2%)
Sources:
20 mg 1 times / day multiple, oral
Recommended
Dose: 20 mg, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg, 1 times / day
Sources:
unhealthy
n = 1145
Health Status: unhealthy
Condition: Essential hypertension
Population Size: 1145
Sources:
Other AEs: Headache, Fatigue...
Other AEs:
Headache (3%)
Fatigue (2%)
Nausea (1%)
Dizziness (3%)
Dizziness postural (1%)
Cough increased (2%)
Sources:
40 mg 1 times / day multiple, oral
Recommended
Dose: 40 mg, 1 times / day
Route: oral
Route: multiple
Dose: 40 mg, 1 times / day
Sources:
unhealthy
n = 771
Health Status: unhealthy
Condition: Essential hypertension
Population Size: 771
Sources:
Other AEs: Headache, Fatigue...
Other AEs:
Headache (3%)
Fatigue (2%)
Nausea (1%)
Dizziness (2%)
Dizziness postural (1%)
Cough increased (1%)
Sources:
5 mg 1 times / day multiple, oral (max)
Recommended
Dose: 5 mg, 1 times / day
Route: oral
Route: multiple
Dose: 5 mg, 1 times / day
Sources:
unhealthy
n = 184
Health Status: unhealthy
Condition: Essential hypertension
Population Size: 184
Sources:
Other AEs: Headache, Dizziness...
Other AEs:
Headache (6%)
Dizziness (2%)
Dizziness postural (2%)
Sources:
80 mg 1 times / day multiple, oral
Recommended
Dose: 80 mg, 1 times / day
Route: oral
Route: multiple
Dose: 80 mg, 1 times / day
Sources:
unhealthy
n = 86
Health Status: unhealthy
Condition: Essential hypertension
Population Size: 86
Sources:
Other AEs: Headache, Fatigue...
Other AEs:
Headache (2%)
Fatigue (5%)
Nausea (1%)
Cough increased (1%)
Sources:
AEs

AEs

AESignificanceDosePopulation
Arthralgia 0.9%
10 mg 1 times / day multiple, oral
Recommended
Dose: 10 mg, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg, 1 times / day
Sources:
unhealthy, adult
n = 116
Health Status: unhealthy
Condition: Essential hypertension
Age Group: adult
Population Size: 116
Sources:
Diarrhoea 0.9%
10 mg 1 times / day multiple, oral
Recommended
Dose: 10 mg, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg, 1 times / day
Sources:
unhealthy, adult
n = 116
Health Status: unhealthy
Condition: Essential hypertension
Age Group: adult
Population Size: 116
Sources:
Fatigue 0.9%
10 mg 1 times / day multiple, oral
Recommended
Dose: 10 mg, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg, 1 times / day
Sources:
unhealthy, adult
n = 116
Health Status: unhealthy
Condition: Essential hypertension
Age Group: adult
Population Size: 116
Sources:
Cough 1.7%
10 mg 1 times / day multiple, oral
Recommended
Dose: 10 mg, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg, 1 times / day
Sources:
unhealthy, adult
n = 116
Health Status: unhealthy
Condition: Essential hypertension
Age Group: adult
Population Size: 116
Sources:
Peripheral oedema 1.7%
10 mg 1 times / day multiple, oral
Recommended
Dose: 10 mg, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg, 1 times / day
Sources:
unhealthy, adult
n = 116
Health Status: unhealthy
Condition: Essential hypertension
Age Group: adult
Population Size: 116
Sources:
Sinusitis 1.7%
10 mg 1 times / day multiple, oral
Recommended
Dose: 10 mg, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg, 1 times / day
Sources:
unhealthy, adult
n = 116
Health Status: unhealthy
Condition: Essential hypertension
Age Group: adult
Population Size: 116
Sources:
Back pain 2.6%
10 mg 1 times / day multiple, oral
Recommended
Dose: 10 mg, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg, 1 times / day
Sources:
unhealthy, adult
n = 116
Health Status: unhealthy
Condition: Essential hypertension
Age Group: adult
Population Size: 116
Sources:
Upper respiratory tract infection 3.4%
10 mg 1 times / day multiple, oral
Recommended
Dose: 10 mg, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg, 1 times / day
Sources:
unhealthy, adult
n = 116
Health Status: unhealthy
Condition: Essential hypertension
Age Group: adult
Population Size: 116
Sources:
Headache 8.6%
10 mg 1 times / day multiple, oral
Recommended
Dose: 10 mg, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg, 1 times / day
Sources:
unhealthy, adult
n = 116
Health Status: unhealthy
Condition: Essential hypertension
Age Group: adult
Population Size: 116
Sources:
Cough increased 2%
10 mg 1 times / day multiple, oral
Recommended
Dose: 10 mg, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg, 1 times / day
Sources:
unhealthy
n = 193
Health Status: unhealthy
Condition: Essential hypertension
Population Size: 193
Sources:
Dizziness 2%
10 mg 1 times / day multiple, oral
Recommended
Dose: 10 mg, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg, 1 times / day
Sources:
unhealthy
n = 193
Health Status: unhealthy
Condition: Essential hypertension
Population Size: 193
Sources:
Fatigue 2%
10 mg 1 times / day multiple, oral
Recommended
Dose: 10 mg, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg, 1 times / day
Sources:
unhealthy
n = 193
Health Status: unhealthy
Condition: Essential hypertension
Population Size: 193
Sources:
Nausea 2%
10 mg 1 times / day multiple, oral
Recommended
Dose: 10 mg, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg, 1 times / day
Sources:
unhealthy
n = 193
Health Status: unhealthy
Condition: Essential hypertension
Population Size: 193
Sources:
Headache 9%
10 mg 1 times / day multiple, oral
Recommended
Dose: 10 mg, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg, 1 times / day
Sources:
unhealthy
n = 193
Health Status: unhealthy
Condition: Essential hypertension
Population Size: 193
Sources:
Dizziness postural 1%
20 mg 1 times / day multiple, oral
Recommended
Dose: 20 mg, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg, 1 times / day
Sources:
unhealthy
n = 1145
Health Status: unhealthy
Condition: Essential hypertension
Population Size: 1145
Sources:
Nausea 1%
20 mg 1 times / day multiple, oral
Recommended
Dose: 20 mg, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg, 1 times / day
Sources:
unhealthy
n = 1145
Health Status: unhealthy
Condition: Essential hypertension
Population Size: 1145
Sources:
Cough increased 2%
20 mg 1 times / day multiple, oral
Recommended
Dose: 20 mg, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg, 1 times / day
Sources:
unhealthy
n = 1145
Health Status: unhealthy
Condition: Essential hypertension
Population Size: 1145
Sources:
Fatigue 2%
20 mg 1 times / day multiple, oral
Recommended
Dose: 20 mg, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg, 1 times / day
Sources:
unhealthy
n = 1145
Health Status: unhealthy
Condition: Essential hypertension
Population Size: 1145
Sources:
Dizziness 3%
20 mg 1 times / day multiple, oral
Recommended
Dose: 20 mg, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg, 1 times / day
Sources:
unhealthy
n = 1145
Health Status: unhealthy
Condition: Essential hypertension
Population Size: 1145
Sources:
Headache 3%
20 mg 1 times / day multiple, oral
Recommended
Dose: 20 mg, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg, 1 times / day
Sources:
unhealthy
n = 1145
Health Status: unhealthy
Condition: Essential hypertension
Population Size: 1145
Sources:
Cough increased 1%
40 mg 1 times / day multiple, oral
Recommended
Dose: 40 mg, 1 times / day
Route: oral
Route: multiple
Dose: 40 mg, 1 times / day
Sources:
unhealthy
n = 771
Health Status: unhealthy
Condition: Essential hypertension
Population Size: 771
Sources:
Dizziness postural 1%
40 mg 1 times / day multiple, oral
Recommended
Dose: 40 mg, 1 times / day
Route: oral
Route: multiple
Dose: 40 mg, 1 times / day
Sources:
unhealthy
n = 771
Health Status: unhealthy
Condition: Essential hypertension
Population Size: 771
Sources:
Nausea 1%
40 mg 1 times / day multiple, oral
Recommended
Dose: 40 mg, 1 times / day
Route: oral
Route: multiple
Dose: 40 mg, 1 times / day
Sources:
unhealthy
n = 771
Health Status: unhealthy
Condition: Essential hypertension
Population Size: 771
Sources:
Dizziness 2%
40 mg 1 times / day multiple, oral
Recommended
Dose: 40 mg, 1 times / day
Route: oral
Route: multiple
Dose: 40 mg, 1 times / day
Sources:
unhealthy
n = 771
Health Status: unhealthy
Condition: Essential hypertension
Population Size: 771
Sources:
Fatigue 2%
40 mg 1 times / day multiple, oral
Recommended
Dose: 40 mg, 1 times / day
Route: oral
Route: multiple
Dose: 40 mg, 1 times / day
Sources:
unhealthy
n = 771
Health Status: unhealthy
Condition: Essential hypertension
Population Size: 771
Sources:
Headache 3%
40 mg 1 times / day multiple, oral
Recommended
Dose: 40 mg, 1 times / day
Route: oral
Route: multiple
Dose: 40 mg, 1 times / day
Sources:
unhealthy
n = 771
Health Status: unhealthy
Condition: Essential hypertension
Population Size: 771
Sources:
Dizziness postural 2%
5 mg 1 times / day multiple, oral (max)
Recommended
Dose: 5 mg, 1 times / day
Route: oral
Route: multiple
Dose: 5 mg, 1 times / day
Sources:
unhealthy
n = 184
Health Status: unhealthy
Condition: Essential hypertension
Population Size: 184
Sources:
Dizziness 2%
5 mg 1 times / day multiple, oral (max)
Recommended
Dose: 5 mg, 1 times / day
Route: oral
Route: multiple
Dose: 5 mg, 1 times / day
Sources:
unhealthy
n = 184
Health Status: unhealthy
Condition: Essential hypertension
Population Size: 184
Sources:
Headache 6%
5 mg 1 times / day multiple, oral (max)
Recommended
Dose: 5 mg, 1 times / day
Route: oral
Route: multiple
Dose: 5 mg, 1 times / day
Sources:
unhealthy
n = 184
Health Status: unhealthy
Condition: Essential hypertension
Population Size: 184
Sources:
Cough increased 1%
80 mg 1 times / day multiple, oral
Recommended
Dose: 80 mg, 1 times / day
Route: oral
Route: multiple
Dose: 80 mg, 1 times / day
Sources:
unhealthy
n = 86
Health Status: unhealthy
Condition: Essential hypertension
Population Size: 86
Sources:
Nausea 1%
80 mg 1 times / day multiple, oral
Recommended
Dose: 80 mg, 1 times / day
Route: oral
Route: multiple
Dose: 80 mg, 1 times / day
Sources:
unhealthy
n = 86
Health Status: unhealthy
Condition: Essential hypertension
Population Size: 86
Sources:
Headache 2%
80 mg 1 times / day multiple, oral
Recommended
Dose: 80 mg, 1 times / day
Route: oral
Route: multiple
Dose: 80 mg, 1 times / day
Sources:
unhealthy
n = 86
Health Status: unhealthy
Condition: Essential hypertension
Population Size: 86
Sources:
Fatigue 5%
80 mg 1 times / day multiple, oral
Recommended
Dose: 80 mg, 1 times / day
Route: oral
Route: multiple
Dose: 80 mg, 1 times / day
Sources:
unhealthy
n = 86
Health Status: unhealthy
Condition: Essential hypertension
Population Size: 86
Sources:
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG

OverviewOther

Other InhibitorOther SubstrateOther Inducer



Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
yes
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
yes
yes
PubMed

PubMed

TitleDatePubMed
Low Dose Combination Therapy vs. High Dose Monotherapy in the Management of Hypertension.
1999 Nov
Renal protective effects of blocking the intrarenal renin-angiotensin system.
1999 Sep
Effect of combination of valsartan with benazepril on blood pressure and left ventricular hypertrophy in SHR.
2000 Nov
Effects of the angiotensin converting enzyme inhibitor benazepril in cats with induced renal insufficiency.
2001 Mar
Spectrophotometric determination of benazepril hydrochloride and hydrochlorothiazide in binary mixture using second derivative, second derivative of the ratio spectra and chemometric methods.
2001 May
Combination of hydrochlorothiazide or benazepril with valsartan in hypertensive patients unresponsive to valsartan alone.
2001 Nov
Treatment of IgA nephropathy with angiotensin converting enzyme inhibitors: design of a prospective randomized multicenter trial.
2001 Nov-Dec
Clinical pharmacokinetics and selective pharmacodynamics of new angiotensin converting enzyme inhibitors: an update.
2002
Effects of losartan and benazepril on abnormal circadian blood pressure rhythm and target organ damage in SHRSP.
2002 Apr
Intensive blood pressure reduction is beneficial in patients with impaired cardiac function coexisting with chronic renal insufficiency.
2002 Jan
Potentiometric and thermal studies of a coated-wire benazepril-selective electrode.
2002 Jan 1
Combination therapy of amlodipine/benazepril versus monotherapy of amlodipine in a practice-based setting.
2002 Jun
Impact of an ACE inhibitor and calcium antagonist on microalbuminuria and lipid subfractions in type 2 diabetes: a randomised, multi-centre pilot study.
2002 Mar
Combination therapy with benazepril and oral adsorbent ameliorates progressive renal fibrosis in uremic rats.
2002 Mar
Self-measured systolic blood pressure in the morning is a strong indicator of decline of renal function in hypertensive patients with non-diabetic chronic renal insufficiency.
2002 May
Fentanyl-associated syndrome of inappropriate antidiuretic hormone secretion.
2002 Sep
[The use of angiotensin-converting enzyme inhibitor benazepril in acute period of myocardial infarction].
2003
Effect of benazepril amlodipine combination on fibrinolysis in hypertensive diabetic patients.
2003 Aug
Gene expression profile revealed different effects of angiotensin II receptor blockade and angiotensin-converting enzyme inhibitor on heart failure.
2003 Dec
Quantitative determination of benazepril and benazeprilat in human plasma by gas chromatography-mass spectrometry using automated 96-well disk plate solid-phase extraction for sample preparation.
2003 Jan 5
Argyria associated with colloidal silver supplementation.
2003 Jul
An angiotensin converting enzyme inhibitor, benazepril can be transformed to an active metabolite, benazeprilat, by the liver of dogs with ascitic pulmonary heartworm disease.
2003 Jun
Results of a pilot pharmacotherapy quality improvement program using fixed-dose, combination amlodipine/benazepril antihypertensive therapy in a long-term care setting.
2003 Jun
[Study on candidate genes of benazepril related cough in Chinese hypertensives].
2003 Jun
Combination is better than monotherapy with ACE inhibitor or angiotensin receptor antagonist at recommended doses.
2003 Mar
[Postmarketing surveillance of benazepril-related cough and related risk factors analysis on hypertensives].
2003 May
Achieving goal blood pressure in patients with type 2 diabetes: conventional versus fixed-dose combination approaches.
2003 May-Jun
Investigation of pimobendan versus benazepril in canine myxomatous valvular disease.
2003 Oct 4
Systemic contact dermatitis due to captopril without cross-sensitivity to fosinopril, quinapril and benazepril.
2004
Combined treatment with an AT1 receptor blocker and angiotensin converting enzyme inhibitor has an additive effect on inhibiting neointima formation via improvement of nitric oxide production and suppression of oxidative stress.
2004 Feb
Patents

Sample Use Guides

The recommended initial dose for patients not receiving a diuretic is 10 mg once a day. The usual maintenance dosage range is 20-40 mg per day administered as a single dose or in two equally divided doses. A dose of 80 mg gives an increased response, but experience with this dose is limited.
Route of Administration: Oral
In Vitro Use Guide
Benazepril inhibited both adrenaline-stimulated aortic PGI2 synthesis (25 pg mg -1 min-1) and carbachol-stimulated urinary bladder PGI2 synthesis (20 pg mg -1 min-1) in dose-dependent manners. IC50 (concentrations of antagonist at which agonist-stimulated PGI2 synthesis was inhibited by 50%) was 8 x 10-5.
Name Type Language
BENAZEPRIL
INN   MI   VANDF   WHO-DD  
INN  
Official Name English
BENAZEPRIL [INN]
Common Name English
CIBACEN WS
Common Name English
BENAZEPRIL [MI]
Common Name English
1H-1-BENZAZEPINE-1-ACETIC ACID, 3-(((1S)-1-(ETHOXYCARBONYL)-3-PHENYLPROPYL)AMINO)-2,3,4,5-TETRAHYDRO-2-OXO-, (3S)-
Common Name English
BENAZEPRIL SANDOZ
Brand Name English
C09AA07
Code English
BENAZEPRIL [VANDF]
Common Name English
BRIEM
Common Name English
BENAZEPRIL [EMA EPAR VETERINARY]
Common Name English
((3S)-3-(((1S)-1-(ETHOXYCARBONYL)-3-PHENYLPROPYL)AMINO)-2-OXO-2,3,4,5-TETRAHYDRO-1H-1-BENZAZEPIN-1-YL)ACETIC ACID
Systematic Name English
CGS-14824A
Code English
CIBACENE
Common Name English
BENAZEPRIL [WHO-DD]
Common Name English
FORTEEKOR
Brand Name English
Classification Tree Code System Code
NDF-RT N0000175562
Created by admin on Sat Jun 26 00:01:53 UTC 2021 , Edited by admin on Sat Jun 26 00:01:53 UTC 2021
EMA VETERINARY ASSESSMENT REPORTS FORTEKOR PLUS [AUHTORIZED]
Created by admin on Sat Jun 26 00:01:53 UTC 2021 , Edited by admin on Sat Jun 26 00:01:53 UTC 2021
NDF-RT N0000000181
Created by admin on Sat Jun 26 00:01:53 UTC 2021 , Edited by admin on Sat Jun 26 00:01:53 UTC 2021
WHO-ATC C09AA07
Created by admin on Sat Jun 26 00:01:53 UTC 2021 , Edited by admin on Sat Jun 26 00:01:53 UTC 2021
NCI_THESAURUS C247
Created by admin on Sat Jun 26 00:01:53 UTC 2021 , Edited by admin on Sat Jun 26 00:01:53 UTC 2021
WHO-VATC QC09AA07
Created by admin on Sat Jun 26 00:01:53 UTC 2021 , Edited by admin on Sat Jun 26 00:01:53 UTC 2021
WHO-ATC C09BA07
Created by admin on Sat Jun 26 00:01:53 UTC 2021 , Edited by admin on Sat Jun 26 00:01:53 UTC 2021
WHO-VATC QC09BA07
Created by admin on Sat Jun 26 00:01:53 UTC 2021 , Edited by admin on Sat Jun 26 00:01:53 UTC 2021
LIVERTOX 93
Created by admin on Sat Jun 26 00:01:53 UTC 2021 , Edited by admin on Sat Jun 26 00:01:53 UTC 2021
Code System Code Type Description
INN
6129
Created by admin on Sat Jun 26 00:01:53 UTC 2021 , Edited by admin on Sat Jun 26 00:01:53 UTC 2021
PRIMARY
WIKIPEDIA
BENAZEPRIL
Created by admin on Sat Jun 26 00:01:53 UTC 2021 , Edited by admin on Sat Jun 26 00:01:53 UTC 2021
PRIMARY
RXCUI
18867
Created by admin on Sat Jun 26 00:01:53 UTC 2021 , Edited by admin on Sat Jun 26 00:01:53 UTC 2021
PRIMARY RxNorm
LACTMED
Benazepril
Created by admin on Sat Jun 26 00:01:53 UTC 2021 , Edited by admin on Sat Jun 26 00:01:53 UTC 2021
PRIMARY
MESH
C044946
Created by admin on Sat Jun 26 00:01:53 UTC 2021 , Edited by admin on Sat Jun 26 00:01:53 UTC 2021
PRIMARY
MERCK INDEX
M2303
Created by admin on Sat Jun 26 00:01:53 UTC 2021 , Edited by admin on Sat Jun 26 00:01:53 UTC 2021
PRIMARY Merck Index
EVMPD
SUB05700MIG
Created by admin on Sat Jun 26 00:01:53 UTC 2021 , Edited by admin on Sat Jun 26 00:01:53 UTC 2021
PRIMARY
DRUG BANK
DB00542
Created by admin on Sat Jun 26 00:01:53 UTC 2021 , Edited by admin on Sat Jun 26 00:01:53 UTC 2021
PRIMARY
PUBCHEM
5362124
Created by admin on Sat Jun 26 00:01:53 UTC 2021 , Edited by admin on Sat Jun 26 00:01:53 UTC 2021
PRIMARY
ChEMBL
CHEMBL838
Created by admin on Sat Jun 26 00:01:53 UTC 2021 , Edited by admin on Sat Jun 26 00:01:53 UTC 2021
PRIMARY
IUPHAR
6374
Created by admin on Sat Jun 26 00:01:53 UTC 2021 , Edited by admin on Sat Jun 26 00:01:53 UTC 2021
PRIMARY
EPA CompTox
86541-75-5
Created by admin on Sat Jun 26 00:01:53 UTC 2021 , Edited by admin on Sat Jun 26 00:01:53 UTC 2021
PRIMARY
FDA UNII
UDM7Q7QWP8
Created by admin on Sat Jun 26 00:01:53 UTC 2021 , Edited by admin on Sat Jun 26 00:01:53 UTC 2021
PRIMARY
DRUG CENTRAL
299
Created by admin on Sat Jun 26 00:01:53 UTC 2021 , Edited by admin on Sat Jun 26 00:01:53 UTC 2021
PRIMARY
CAS
86541-75-5
Created by admin on Sat Jun 26 00:01:53 UTC 2021 , Edited by admin on Sat Jun 26 00:01:53 UTC 2021
PRIMARY
NCI_THESAURUS
C61645
Created by admin on Sat Jun 26 00:01:53 UTC 2021 , Edited by admin on Sat Jun 26 00:01:53 UTC 2021
PRIMARY